Baseline Characteristics
Among the original 1120 HFpEF patients enrolled, we identified total 960 HFpEF patients (76.4±12.7 years, men: 37.2%) with fQRS classification available as non-fQRS (68.4%), inferior fQRS (22.9%), and anterior/lateral fQRS (8.7%) without overt BB and after application of our exclusion criteria (Table 1). Compared to those classified as non-fQRS, patients with inferior fQRS group had higher systolic blood pressure and were more likely to have diabetes mellitus; patients with anterior/lateral fQRS had higher serum potassium level and were more likely to have atrial fibrillation (Table 1), while other baseline demographics were comparable. We also observed graded and significantly higher BNP and troponin I levels across the three categories (non-fQRS, inferior fQRS, anterior/later fQRS, BNP: 554 vs 581 vs 893 pg/mL; troponin-I: 0.04 vs 0.04 vs 0.06 as median [IQR] ranges, aall trend p < 0.01). Baseline demographics according to QRS duration strata cutoff: 110ms) were detailed in Table S1.
Table 1
Baseline characteristics of study subjects categorized by the location of fragmented QRS
Fragmented QRS Groups
|
Non-fQRS
(N=657)
|
Inferior fQRS
(N=220)
|
Anterior/lateral fQRS
(N=83)
|
p value (ANOVA)
|
Demographics
|
|
|
|
|
Age
|
76.7±12.8
|
75.8±12.5
|
75.6±12.6
|
0.41
|
Gender, male (%)
|
238(36.2%)
|
86(39.1%)
|
33(39.8%)
|
0.52
|
BMI kg/m2
|
24.6±5.5
|
25.3±5.7
|
24.4±11.2
|
0.04
|
SBP, mmHg
|
139.5±32.3
|
146.1±32.8*
|
138.8±34.3
|
0.02
|
DBP, mmHg
|
72.6±17.5
|
74.4±18.8
|
73.5±19.8
|
0.41
|
HR, bpm
|
90.4±2.3
|
88.8±19.3
|
94.7±4.9
|
0.09
|
History, n (%)
|
|
|
|
|
Prior heart failure
|
362(55.1%)
|
118(53.6%)
|
46(55.4%)
|
0.89
|
Hypertension
|
469(71.4%)
|
171(77.7%)
|
61(73.5%)
|
0.22
|
Diabetes mellitus
|
315(47.9%)
|
127(58.0%)
|
39(47.0%)
|
0.03
|
Coronary artery disease
|
215(32.7%)
|
76(34.7%)
|
34(41.0%)
|
0.31
|
ESRD/Hemodialysis
|
72(11.0%)
|
26(11.8%)
|
16(19.3%)
|
0.16
|
Hyperlipidemia treatment
|
118(18.0%)
|
47(21.4%)
|
12(14.5%)
|
0.31
|
Stroke
|
111(16.9%)
|
39(17.7%)
|
17(20.5%)
|
0.71
|
Atrial fibrillation
|
132(20.1%)
|
36(16.4%)
|
24(28.9%)†
|
0.09
|
PAD
|
44(6.7%)
|
16(7.3%)
|
5(6.0%)
|
0.91
|
Laboratory
|
|
|
|
|
Fasting glucose, mg/dl
|
170.1±108.1
|
184.5±114.6
|
192.4±131.3
|
0.09
|
eGFR, ml/min/1.73m2
|
42.1±32.9
|
39.0±32.9
|
39.0±32.4
|
0.41
|
ALT, u/l
|
52.7±108.0
|
78.6±200.4
|
87.3±261.1
|
0.03
|
Serum sodium, mmol/L
|
131.0±8.4
|
129.9±7.7
|
129.2±9.2
|
0.10
|
Serum potassium, mmol/L
|
5.2±1.2
|
5.4±1.3
|
5.6±1.3*
|
0.007
|
BNP, pg/mL (n=917)a
|
554[256, 1170]
|
581[246, 1330]
|
893[478, 2740]*†
|
<0.001
|
Troponin I (n=887)a
|
0.03[0.02, 0.1]
|
0.04[0.02, 0.12]
|
0.06[0.03, 0.23]*†
|
0.008
|
QRS duration, ms
|
92.3±15.0
|
94.2±15.3
|
97.8±17.3*
|
0.005
|
NYHA Fc
|
|
|
|
0.061
|
≤ II
|
14.3%
|
14.5%
|
12.0%
|
|
III
|
62.2%
|
60.0%
|
49.4%
|
|
IV
|
23.4%
|
25.4%
|
38.6%
|
|
Measurement
|
|
|
|
|
LVEF, %
|
64.7±6.3
|
64.8±6.7
|
64.1±7.1
|
0.66
|
Prognostic nutritional score
|
41.3±9.1
|
41.3±8.9
|
40.0±9.4
|
0.43
|
Medications, n (%)
|
|
|
|
|
ACEI/ARB
|
220(33.5%)
|
83(37.7%)
|
27(32.5%)
|
0.45
|
Beta-blocker
|
133(20.2%)
|
48(21.8%)
|
14(16.8%)
|
0.73
|
Aldosterone antagonists
|
105(16.0%)
|
39(17.7%)
|
11(13.3%)
|
0.61
|
Digoxin
|
34(5.2%)
|
14(6.4%)
|
7(8.4%)
|
0.43
|
Diuretics
|
297(45.2%)
|
105(47.7%)
|
28(33.7%)
|
0.05
|
Data are expressed as mean ± SD or percentage. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II-receptor blocker; BNP, B-type natriuretic peptide; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HR, heart rate; LVEF, left ventricular ejection fraction; PAD, peripheral arterial disease; SBP, systolic blood pressure. |
* p<0.05 vs Non-fQRS; † p<0.05 vs Inferior fQRS. |
a Troponin-I and BNP are expressed as median [25th percentile, 75th percentile] |
Cardiac Structure and Function
Compared to those classified as non-fQRS, HFpEF patients with anterior/lateral fQRS had a substantially larger LV EDVi (48.9±17.0 mL vs 44.2±13.8 mL, p < 0.05), greater LV mass-to-volume ratio (2.21±0.68 vs. 2.19±0.84, p < 0.05), and had significantly lower myocardial relaxation velocity TDI-e’ (4.8±1.9 vs 5.7±1.8 cm/s, p < 0.05). Both patient groups with inferior and anterior/lateral fQRS presented with a significantly larger LV mass (174.9±60.7 and 180.2±75.1 gm vs. 162.8±58.6 gm, trend p = 0.004), with those with anterior/lateral fQRS had significantly larger indexed LV mass and were more likely to have LVH compared to non-fQRS (39.6% and 49.4% vs. 34.7%, trend p = 0.027). Furthermore, compared to those classified as non-fQRS/inferior fQRS, HFpEF patients with anterior/lateral fQRS showed a substantially lower myocardial systolic velocity TDI-s’(trend p = 0.001), higher LV filling E/e’(20.4±9.8 vs 16.1±7.0 and 16.5±7.1, trend p < 0.001), higher TR velocity (3.2±0.6 m/s vs 3.0±0.4 and 3.0±0.4 m/s, trend p = 0.010), larger RA/LA indexed volumes ( both trend p < 0.05; LA indexed volume: 33.0±15.0 mL/m2 vs 28.3±13.3 and 28.0±11.9 mL/m2, trend p = 0.010), and a greater RV end-diastolic/systolic area (both trend p < 0.001). (Table 2) In addition, compared to non-fQRS, those presenting with anterior/lateral fQRS had significantly lower RVFAC (p = 0.015). Overall, more unfavorable cardiac structural and functional indices were found in those presenting wider (>110ms) compared to those with smaller QRS duration (≤ 110ms), though these differences were less prominent compared to fQRS strata (Table S2).
Table 2
The LV/RV structure and function in non-fQRS, inferior fQRS, and anterior/lateral fQRS groups
Fragmented QRS Groups
|
Non-fQRS
(N=657)
|
Inferior fQRS
(N=220)
|
Anterior/lateral fQRS
(N=83)
|
p value (ANOVA)
|
LV Structure
|
|
|
|
|
Septal wall thickness, mm
|
9.9±2.0
|
10.2±2.0
|
10.4±1.9
|
0.015
|
Posterior wall thickness, mm
|
10.0±2.0
|
10.3±2.0
|
10.3±1.9
|
0.039
|
LV internal dimension, mm
|
46.3±6.1
|
47.0±6.2
|
47.7±6.7
|
0.080
|
LV EDV index, mL
|
44.2±13.8
|
45.2±15.5
|
48.9±17.0*
|
0.028
|
LV ESV index, mL
|
15.0±8.7
|
15.1±9.9
|
17.3±11.8
|
0.120
|
LVEF, %
|
67.9±13.6
|
69.2±14.2
|
67.6±15.4
|
0.450
|
LV mass, gm
|
162.8±58.6
|
174.9±60.7*
|
180.2±75.1*
|
0.004
|
LV mass index, gm/m2
|
94.2±30.8
|
99.4±32.7
|
105.3±39.5*
|
0.004
|
Presence of LVH (%)
|
216(32.9%)
|
84(38.2%)
|
39(47.0%)
|
0.027
|
LV M/V ratio
|
2.2±0.8
|
2.3±1.0
|
2.2±0.7*
|
0.684
|
LV function
|
|
|
|
|
Mitral E/A ratio
|
1.2±1.5
|
1.1±0.8
|
1.2±0.8
|
0.370
|
DT, ms
|
210.8±77.3
|
211.1±74.8
|
206.7±79.9
|
0.892
|
IVRT, ms
|
85.9±33.4
|
87.5±30.5
|
91.5±34.3
|
0.312
|
TDI-e’
|
5.7±1.8
|
5.4±1.8
|
4.8±1.9*
|
0.001
|
TDI-s’
|
5.7±1.4
|
5.6±1.3
|
5.0±1.3*†
|
0.001
|
Mitral E/TDI-e’
|
16.1±7.0
|
16.5±7.1
|
20.4±9.8*†
|
<0.001
|
TR Velocity, cm/s
|
3.0±0.4
|
3.0±0.5
|
3.2±0.6*†
|
0.010
|
RV structure and function
|
|
|
|
|
RV EDA, cm2
|
30.5±13.1
|
31.9±13.5
|
37.3±16.3*†
|
<0.001
|
RV ESA, cm2
|
16.1±8.7
|
16.9±9.0
|
20.9±11.9*†
|
<0.001
|
RV FAC, %
|
48.4±7.9
|
47.9±8.4
|
45.5±8.4*
|
0.015
|
Atrial structure
|
|
|
|
|
LA Volume index, mL/m2
|
28.3±13.3
|
28.0±11.9
|
33.0±15.0*†
|
0.010
|
RA Volume index, mL/m2
|
22.9±14.8
|
22.4±20.3
|
28.3±18.2*†
|
0.022
|
Data are expressed as mean ± SD or percentage. All expressions are listed in Table 1. |
* p<0.05 vs Non-fQRS; † p<0.05 vs Inferior fQRS. |
LV, left ventricular; RV, right ventricular; EDV, end-diastolic volume; EDA, end-diastolic area; ESA, end-systolic area; FAC, fractional area change; ESV, end-systolic volume; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LV, left ventricular mass to volume ratio; DT, deceleration time; IVRT, interventricular relaxation time; LA, left atrial; RA, right atrial; TDI, tissue Doppler imaging; TR, tricuspid regurgitation. |
Myocardial Perfusion and Coronary Flow Findings
Despite comparable CAD prevalence, HFpEF patients categorized into inferior fQRS and anterior/lateral fQRS had a graded increase in post-stress total myocardial perfusion defect when compared to the non-fQRS group (Figure 1A, trend p = 0.001). By examining individual myocardial perfusion defects according to coronary artery territories, HFpEF patients categorized into anterior/lateral fQRS were more likely to have fixed myocardial perfusion defects from the LAD/LCX coronary territory compared to the RCA territory (40%, 40% vs. 13.3%), with those HFpEF patients categorized into inferior fQRS tend to have fixed perfusion defects close to LCX/RCA coronary territory compared to LAD (38.1%, 33.3% vs. 19%). HFpEF classified as non-fQRS was less likely to present myocardial perfusion defects on three coronary arterial territories (all <20%) (Figure 1B-D).
Illustrations of myocardial perfusion deficit by SPECT are displayed in Figure 2A-C. The burden of myocardial perfusion defect was inversely correlated with TDI-s’ (r = -0.15, p = 0.02), showing a borderline reverse relationship with TDI-e’ (r = -0.11, p = 0.08), with a non-significant positive relationship with E/TDI-e’ (r = 0.05, p = 0.46) (Figure 2D-F). Overall, 67 out of 203 (33%) symptom-driven HFpEF patients did not have a significant CAD manifested slow flow phenomenon, with a graded and significantly higher proportion observed across non-fQRS, inferior fQRS, and anterior/lateral fQRS (28%, 50%, and 83.3%, respectively, X2 < 0.001) (Figure 3A). Interestingly, substantially lower myocardial TDI-e’ and TDI-s’ were associated with a higher LV filling pressure (E/TDI-e’) in those HFpEF patients without CAD manifesting slow coronary flow (Figure 3B-D).
Clinical Outcomes
During a median follow-up of 657 days (IQR: 70–1274 days), 314 patients (32.7%) were hospitalized for HF, 178 (18.5%) experienced CV death, 337 (35.1%) experienced all-cause death, and 585 (60.9%) had composite events of HF hospitalization and mortality irrespective of any cause. A Cox proportional hazard regression analysis for adverse events is shown in Figure 4 and Table S3. By using non-fQRS as the reference group, the presence of anterior/lateral fQRS was associated with a higher risk of HHF (adjusted HR: 1.90 [1.34, 2.69], p < 0.001), with the presence of both inferior fQRS and anterior/lateral fQRS associated with a higher risk of CV (adjusted HR: 1.44 [1.02, 2.05] and 2.00 [1.26, 3.16] for inferior and anterior/lateral fQRS, respectively), and all-cause mortality (adjusted HR: 1.35 [1.04, 1.74] and 1.84 [1.32, 2.56] for inferior and anterior/lateral fQRS, respectively) in multivariate model with adjustment for age, gender, body mass index, hypertension, diabetes mellitus, heart failure, hyperlipidemia, cardiovascular disease, estimated glomerular filtration rate, LV ejection fraction;. Kaplan-Meier survival curves for relevant clinical outcomes according to fQRS strata are displayed in Figure 5 (left) (all log-rank p < 0.001). Clinical outcomes according to QRS duration strata (cutoff: 110ms) were detailed in Table S4, where risk stratification by QRS duration cutoff (110ms) were less prominent compared to fQRS.